PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-9.50%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
8.09%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
-15.22%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.22%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
12.56%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
14.68%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
14.47%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-1.98%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.72%
Reduced diluted shares while CVE is at 0.43%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-6.54%
Dividend reduction while CVE stands at 98.18%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-9.04%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
14.63%
Positive FCF growth while CVE is negative. John Neff would see a strong competitive edge in net cash generation.
19.07%
10Y revenue/share CAGR under 50% of CVE's 55.54%. Michael Burry would suspect a lasting competitive disadvantage.
108.65%
5Y revenue/share CAGR 1.25-1.5x CVE's 84.47%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
115.36%
3Y revenue/share CAGR 1.25-1.5x CVE's 86.22%. Bruce Berkowitz might see better product or regional expansions than the competitor.
-27.39%
Negative 10Y OCF/share CAGR while CVE stands at 55.11%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
86.39%
5Y OCF/share CAGR at 75-90% of CVE's 112.40%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
25.77%
3Y OCF/share CAGR under 50% of CVE's 158.32%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
1092.89%
Net income/share CAGR above 1.5x CVE's 363.02% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
558.23%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
23446.77%
3Y net income/share CAGR above 1.5x CVE's 346.55%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-13.60%
Negative equity/share CAGR over 10 years while CVE stands at 11.33%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-10.17%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-18.75%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-78.01%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
205.07%
5Y dividend/share CAGR at 50-75% of CVE's 343.15%. Martin Whitman might see a lagging policy in mid-term shareholder returns.
128.06%
3Y dividend/share CAGR at 50-75% of CVE's 251.07%. Martin Whitman might see a weaker short-term approach to distributing cash.
-9.15%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
No Data
No Data available this quarter, please select a different quarter.
4.74%
Asset growth above 1.5x CVE's 1.42%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
19.76%
BV/share growth above 1.5x CVE's 0.31%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.75%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-0.99%
We cut SG&A while CVE invests at 150.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.